Monopar Therapeutics assumed with a Buy at H.C. Wainwright

H.C. Wainwright assumed coverage of Monopar Therapeutics (MNPR) with a Buy rating and $70 price target The firm views ALXN1840 as “profoundly misunderstood” and believes the therapy is positioned for a new drug application submission in early 2026. The analyst is constructive that ALXN1840 can become the first major therapeutic advance in Wilson disease in over three decades.